Scholarlink

<p>Dry eye disease (DED) is a chronic ocular surface disorder characterized by Th17/Treg cells imbalance, particularly prevalent among elderly females. Current treatment approaches are evolving from merely providing symptomatic relief to targeting immune dysfunction. Mesenchymal stem cell-derived exosomes (MSC-Exos) have demonstrated the ability to modulate the immune response and promote corneal epithelial cell regeneration in DED. Nonetheless, the precise mechanism through which MSC-Exos exert these effects is not yet fully understood. Consequently, the objective of this study was to explore the mechanisms behind the therapeutic effects of umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exos) in a murine model of DED. We discovered that UCMSC-Exos stimulated human corneal epithelial cell lines wound healing in vitro. The topical or systemic administration of UCMSC-Exos significantly altered cytokine expression by neutrophils, leading to a reduction in proinflammatory cytokine expression and an increase in anti-inflammatory cytokine expression. This shift in the cytokine profile reestablished the Treg/Th17 cells balance, resulting in decreased inflammation and alleviation of DED symptoms, with younger mice showing more pronounced benefits. These results highlight the potential of UCMSC-Exos as a therapeutic approach for DED that modulates immune dysregulation and enhances ocular surface repair.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

UCMSC-derived exosomes ameliorate dry eye disease pathogenesis by modulating neutrophils on Th17/Treg balance

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年2月5日

查看全文
  • Yuxing Gong,
  • Yufei Ding,
  • Jingyi Yang,
  • Tao Ding,
  • Bin Li,
  • Junfeng Ma,
  • Wahid Shah,
  • Youcai Deng,
  • Ping Duan,
  • Yu Zhang,
  • Yuan Gao

摘要

Dry eye disease (DED) is a chronic ocular surface disorder characterized by Th17/Treg cells imbalance, particularly prevalent among elderly females. Current treatment approaches are evolving from merely providing symptomatic relief to targeting immune dysfunction. Mesenchymal stem cell-derived exosomes (MSC-Exos) have demonstrated the ability to modulate the immune response and promote corneal epithelial cell regeneration in DED. Nonetheless, the precise mechanism through which MSC-Exos exert these effects is not yet fully understood. Consequently, the objective of this study was to explore the mechanisms behind the therapeutic effects of umbilical cord mesenchymal stem cell-derived exosomes (UCMSC-Exos) in a murine model of DED. We discovered that UCMSC-Exos stimulated human corneal epithelial cell lines wound healing in vitro. The topical or systemic administration of UCMSC-Exos significantly altered cytokine expression by neutrophils, leading to a reduction in proinflammatory cytokine expression and an increase in anti-inflammatory cytokine expression. This shift in the cytokine profile reestablished the Treg/Th17 cells balance, resulting in decreased inflammation and alleviation of DED symptoms, with younger mice showing more pronounced benefits. These results highlight the potential of UCMSC-Exos as a therapeutic approach for DED that modulates immune dysregulation and enhances ocular surface repair.